BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Nordic AML Group - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nordic AML Group
X-ORIGINAL-URL:https://www.namlg.org
X-WR-CALDESC:Events for Nordic AML Group
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240312T150000
DTEND;TZID=Europe/Paris:20240312T170000
DTSTAMP:20260416T052819
CREATED:20240213T194106Z
LAST-MODIFIED:20240304T122131Z
UID:10000008-1710255600-1710262800@www.namlg.org
SUMMARY:Nordic AML 'poster walk' post-ASH
DESCRIPTION:Nordic AML posters at ASH 2023 – Webinar – 2024-03-12 – 15:00-16:20 (CET) \nJoin us for a webinar where we delve into the intricacies of showcased Nordic AML posters at the latest ASH Annual Meeting in December 2023. Here we aim for an opportunity to gain valuable insights\, connect with peers\, and stay at the forefront of AML innovation. \n\nJoin via Zoom: https://uu-se.zoom.us/j/63956689621 \n\nTentative agenda (updated 2024-03-04) \n15:00 – 15:05 – Welcome \n15:05 – 15:15 – Elory Leonard\, Stockholm\, Sweden \nProtective Function of Human Skin Mesenchymal Niches for Acute Myeloid Leukemia-Initiating Stem Cells \n15:15 – 15:25 – Ida Vänttinen\, Helsinki\, Finland \nTargeting Venetoclax Resistance in TP53-Mutated Acute Myeloid Leukemia \n15:25 – 15:35 – Claudia Schöllkopf\, Copenhagen\, Denmark \nDose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) \n15:35 – 15:45 – Sofie Johansson Alm\, Gothenburg\, Sweden \nDeep Sequencing Is a Widely Applicable Tool for Relapse Prediction in Acute Myeloid Leukemia with Mutated NPM1 \n15:45 – 15:55 – Øystein Sefland\, Bergen\, Norway \nIntradermal Vaccination with Vididencel in MRD+ AML-Patients Leads to Increase in Antigen Presenting Cells and T-Cells to the Injection Site\, Visualized Using Imaging Mass Cytometry\, Showing Local Immune Cell Interactions Leading to Systemic Immune Responses \n15:55 – 16:05 – Hanna Duàn\, Helsinki\, Finland \nPrimary Acute Myeloid Leukemia Cells Trigger Distinct Activation Patterns in Expanded NK Cells \n16:05 – 16:15 – Somadri Ghosh\, Lund\, Sweden \nH2-K1 on MLL-AF9 Leukemia Cells Facilitates the Escape of NK Cell-Mediated Immune Surveillance \n16:15 – 16:25 – Jonas Bouhlal\, Helsinki\, Finland \nHigh-Throughput Screens Identify NEDD8 Inhibition As a Strategy to Augment Natural Killer Cell Cytotoxicity Against Blood Cancers \n16:25 – 16:30 – Closing remarks \n\nArranged by the NAMLG Educational Working Group (namlgewg@gmail.com)
URL:https://www.namlg.org/event/nordic-aml-poster-walk-post-ash/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240125T160000
DTEND;TZID=Europe/Paris:20240125T170000
DTSTAMP:20260416T052819
CREATED:20240124T102108Z
LAST-MODIFIED:20240124T102108Z
UID:10000006-1706198400-1706202000@www.namlg.org
SUMMARY:Early Response Evaluation by Single-Cell Signaling Profiling in AML
DESCRIPTION:Webinar to be held January 25 at 16:00 \nThis is in Standard Biotools’ (former Fluidigm) Scientist in the Spotlight series. \nMore info and registration on this link. \nHear about: \nInsights into AML response: Discover the initial signaling response to standard induction chemotherapy in a cohort of 32 AML patients. \n  \nPredicting 5-year survival: Learn about the significant predictors of patient 5-year overall survival in this cohort\, specifically the reduction of extracellular-signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK) phosphorylation. \n  \nImportance of signaling pathways: See how RNA sequencing and proteomics confirm the mass cytometry data and highlight the potential for this assay to be used in the future of precision oncology.
URL:https://www.namlg.org/event/early-response-evaluation-by-single-cell-signaling-profiling-in-aml/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240124T153000
DTEND;TZID=Europe/Paris:20240124T163000
DTSTAMP:20260416T052819
CREATED:20240124T110456Z
LAST-MODIFIED:20240124T110456Z
UID:10000007-1706110200-1706113800@www.namlg.org
SUMMARY:NAMLG TWG Meeting - I - 24-01-2024  15:30-16:30 CET
DESCRIPTION:Link and passcode for Teams meeting sent separately. \nAgenda: \n\nUpdate on potential LD-VenEx amendment trial comparing poDEC/LD-VenEx vs. AZA/LD-VenEx (5 min + 10 min discussion).\nNAMLG – platform trial structure concept (5 min): Infrastructure with standing collaboration contracts (clinical trial agreement – CTA) and data processing agreements (DPAs) applicable for all types of trials. This would allow to open trials at one Nordic sponsor site and recruit pts from all Nordic Sites without the requirement to establish new CTAs / DPAs for each trial with individually. Ultimately\, this will establish the NAMLG as partner for pharma-sponsored trials as well as to obtain funding for IIT.\nList/overview of ongoing\, already planned\, and potential future AML trials in the Nordics.\nPresentation and discussion of ongoing and potential novel AML trials\n\nMartin Jädersten – Salvage Treatment + HU (5 min + 5 min discission\nOxcia: Presentation of MAATEO Karonudib + Dauno for RR AML (7 min+ 3 min discussion)\nTrials suggested in previous mail by Bjørn Tore Gjertsen (6 min + 4 min discussion)
URL:https://www.namlg.org/event/namlg-twg-meeting-i-24-01-2024-1530-1630-cet/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20231206T153000
DTEND;TZID=Europe/Paris:20231206T163000
DTSTAMP:20260416T052819
CREATED:20231201T074717Z
LAST-MODIFIED:20240316T192439Z
UID:10000005-1701876600-1701880200@www.namlg.org
SUMMARY:Webinar - Immunotherapy: a new perspective for AML maintenance treatment?
DESCRIPTION:Agenda \n[Post updated 2024-03-16] \nDownload a recorded version of the webinar using this link. \nFind the HCP guide for Ceplene on this link. \nCeplene can be ordered with the Nordic item number (Vnr.) 46 54 33\, through: \nOriola in Sweden\nTMJ in Denmark\nYour local wholesaler\, Apotek 1\, NMD and Alliance in Norway \n——————————————— \nAML patients not candidates to allotransplant: relapse risk and therapeutics (Pr Bjorn Gjertsen) \nImmunotherapy with Histamine dihydrochloride in association with low-dose interleukin-2 (HDC/IL-2) for relapse prevention (Pr Kristoffer Hellstrand) \nConceivable indications of HDC/IL-2 for post-remission in AML? (Pr Bjorn Gjertsen\, Dr Martin Jädersten\, Dr Lovisa Wennström) \nFor more info\, click here. \nFor registration\, click here.
URL:https://www.namlg.org/event/webinar-immunotherapy-a-new-perspective-for-aml-maintenance-treatment/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20231130T120000
DTEND;TZID=Europe/Paris:20231130T210000
DTSTAMP:20260416T052819
CREATED:20231123T100038Z
LAST-MODIFIED:20231123T100446Z
UID:10000003-1701345600-1701378000@www.namlg.org
SUMMARY:Myeloid Neoplasia StemCellTransplant (MNSCT) Nordic workshop
DESCRIPTION:We are thrilled to invite you all to the first MNSCT workshop. The program is planned by a scientific committee from the Swedish-Norwegian BMT-group and the Swedish AML-group. The overarching aim of this meeting is to stimulate discussions around topics within the Nordic community. \nPlease register for this event using this link (deadline 2023-10-27). \nClick here for more information and the program. \nThe workshop is supported by medac Nordics.
URL:https://www.namlg.org/event/myeloid-neoplasia-stemcelltransplant-mnsct-nordic-workshop/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20231108T080000
DTEND;TZID=Europe/Paris:20231108T170000
DTSTAMP:20260416T052819
CREATED:20231123T095916Z
LAST-MODIFIED:20231123T095916Z
UID:10000002-1699430400-1699462800@www.namlg.org
SUMMARY:Nordic AML webinar
DESCRIPTION:Thank you to all participants for taking part in the Nordic AML webinar 2023-11-08. For a recording of the webinar use this link.
URL:https://www.namlg.org/event/nordic-aml-webinar/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20231010T080000
DTEND;TZID=Europe/Paris:20231010T170000
DTSTAMP:20260416T052819
CREATED:20231123T102511Z
LAST-MODIFIED:20231123T102511Z
UID:10000004-1696924800-1696957200@www.namlg.org
SUMMARY:MRD webinar
DESCRIPTION:Thank you to the panelists of our MRD webinar 2023-10-10. For a recording of the webinar use this link.
URL:https://www.namlg.org/event/mrd-webinar/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230824
DTEND;VALUE=DATE:20230826
DTSTAMP:20260416T052819
CREATED:20231123T094750Z
LAST-MODIFIED:20231123T095448Z
UID:10000001-1692835200-1693007999@www.namlg.org
SUMMARY:Nordic AML Meeting 2023
DESCRIPTION:Registration \nDay 1: Thursday August 24\, 2023\n09:45-10:00:    Welcome and Opening: Bjørn Tore Gjertsen (Chair\, Nordic AML Group) \nSession 1: Chairs: Bjørn Tore Gjertsen\, Jeffrey Tyner\n10:00-10:30:    NAMLG Keynote Lecture \n                           Sören Lehmann: Chromatin organization – the next step in the characterization of AML \n10:30-10:50:    Jorrit Enserink: Drug sensitivity Screen in AML undergoing intensive chemotherapy \n10:50-11:10:    Krister Wennerberg: Repurposing through drug sensitivity screen in AML \n11:10-11:30:    Caroline Heckman: Contextual factors in drug sensitivity screen \n11:30-11:50:    Päivi Östling: Harmonization of Drug sensitivity Screen \nSession 2: Chair: Mika Kontro\, Kim Theilgaard-Mönch\n11:50-12:20:    Martin Jädersten: Real world use of venetoclax \n12:20-12:40:    Kim Theilgaard-Mönch: Interim analysis of the NAMLG trial LD-VenEx \n12:40-13:30:    NAMLG Keynote Lecture \n                           Daniel A Pollyea: Venetoclax in AML: Current state of the art and future development \n13:30-14:30:   LUNCH BREAK\nSession 3: Chairs: Sören Lehmann\, Oscar Brück\n14:30-14:50:    Tom Erkers: Data driven hallmarks in AML \n14:50-15:10:    Thoas Fioretos: Harnessing the Power of Genomics for Improved  Precision Medicine                                                \n15:10-15:40    COFFEE BREAK\nSession 4: Chairs: Bjørn Tore Gjertsen\, Karl-Johan Malmberg \n15:40-16:10:    Mohn Research Centre for Regenerative Medicine (MRCRM) Keynote Lecture \n                           Gunnar Kvalheim: WT1/PRAME RNA-loaded dendritic cell vaccine in AML \n16:10-16:30:   Karl-Johan Malmberg: NK immunotherapy in AML \n16:30-16:50:    Sébastien Walchli: CAR T in AML \n18:10-19:15 RECEPTION IN HAAKONSHALLEN\, BERGEN MUNCIPALITY\n19:45            CONFERENCE DINNER\n______________________________________________________________________ \nDay 2: Friday August 25\, 2023\nSession 5: Chairs: Anne-Sophie von Krogh\, Marianne Tang Severinsen\n08:15-08:45:     Gunnar Juliusson: Challenges of the new AML classifications and guidelines \n08:45 – 09:00:  Discussion \n09:00 – 09:30:  NAMLG Keynote Lecture  \n                             Gerwin Huls: AML therapy backbone and the future of targeted therapies \n09:30 – 09:50: Hans Beier Ommen: Measurable residual disease monitoring \n09:50 – 10:10:  Marianne Tang Severinsen: Registries in AML and a Nordic cohort of AML \n10:10 – 10:40:  Oscar Brück: Data Lake and collection of data for real world epidemiology \n10:40 – 11:10 COFFEE BREAK\nSession 6: Chairs: Caroline Heckman\, JJ Schuringa\n11:10 – 11:40:  NAMLG Keynote Lecture  \n                           J.J. Schuringa: Tumor-stromal interactions in AML \n11:40 – 12:00:  Mika Kontro: Novel macrophage re-programmer bexmarilimab in myeloid malignancies \n12:00 –12:30:  CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB \n                            Jeffrey Tyner: Big data for novel therapeutic strategies in myeloid malignancies \n12:30 – 13:30: LUNCH BREAK\nSession 7: Chairs: James Lorens\, Krister Wennerberg\n13:30 – 13:45: James Lorens: Axl as therapeutic target in cancer \n13:45 – 14:15: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB \n                          Sonia Loges: AXL in AML \n14:15 – 14:45: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB  \n                          Uwe Platzbecker: Bemcentinib and Axl in MDS and AML. \nSession 8: Chairs: Jean Christoph Bourdon; Andrea Lenartova\n14:45 – 15:05: Jean Cristoph Bourdon: p53 and its isoforms in cancer \n15:05 – 15:45: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB \n                          Eva Hellström-Lindberg: TP53 mutations in MDS and AML \n15:45 – 16:15 COFFEE BREAK\nSession 9: Chair: Pia Ettala\, Vladimir Lazarevic \n16:15 – 16:45:  Martin Höglund: The therapeutic landscape in the Nordics: fit and unfit patients in a regional collaboration \n16:45 – 17:00: Closing remarks: Mika Kontro\, Secretary\, NAMLG \nRegistration
URL:https://www.namlg.org/event/nordic-aml-meeting-2023/
LOCATION:Radisson BLU Royal Hotel\, Bergen\, Norway
ATTACH;FMTTYPE=image/jpeg:https://www.namlg.org/wp-content/uploads/2022/09/bryggenibergen.jpg
END:VEVENT
END:VCALENDAR